Medtronic (MDT) Stock Dips While Market Gains: Key Facts

In the latest close session, Medtronic (MDT) was down 1.81% at $91.22. This move lagged the S&P 500's daily gain of 0.32%. Elsewhere, the Dow saw an upswing of 0.3%, while the tech-heavy Nasdaq appreciated by 0.66%.

Shares of the medical device company have appreciated by 10.31% over the course of the past month, outperforming the Medical sector's gain of 6.56%, and the S&P 500's gain of 3.34%.

The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. It is anticipated that the company will report an EPS of $1.39, marking a 10.32% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.47 billion, showing a 10.4% escalation compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.94 per share and a revenue of $38.64 billion, signifying shifts of +7.41% and +6.26%, respectively, from the last year.

Investors might also notice recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).

In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 15.63. Its industry sports an average Forward P/E of 21.32, so one might conclude that Medtronic is trading at a discount comparatively.

It's also important to note that MDT currently trades at a PEG ratio of 2.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 2.12 as trading concluded yesterday.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 42% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research